These findings formed the basis for international guidelines to recommend that all patients with metastatic CRC should be tested for KRAS exon 2/3/4 mutations and that patients detected with mutations in any of these exons should not be treated with anti-EGFR therapy. The gene discussed is KRAS; the disease is colorectal carcinoma.